Phase 2 Head and Neck Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to sign and date a consent form for the study
- People who are willing to follow all study procedures and are available for the full duration of the study
- People who have a good general health status, able to carry out normal daily activities with little or no limitation (known as ECOG performance status 0 or 1)
- People who have been diagnosed through a tissue or cell sample with a type of cancer called squamous cell carcinoma, located in the mouth, throat, voice box, or with an unknown starting point in the neck
- People whose cancer can be measured either at the main tumour site or in the neck, using standard imaging measurements
- People who have adequate blood, liver, and kidney function, if they are planned to receive chemotherapy as part of the trial (specific levels are outlined in the study protocol)
- People whose blood clotting levels fall within the normal range within 28 days before joining the trial — people taking blood-thinning medications such as warfarin may still be considered if their dose is stable and there are no known clotting problems
- Women who could potentially become pregnant must have a negative pregnancy blood test before starting the study treatment
Who may not be able to join:
- People who are currently pregnant or breastfeeding
- People who have previously received radiation therapy to the head or neck, or any prior systemic treatment (such as chemotherapy or immunotherapy) for the cancer being studied
- People who have already had surgery intended to fully remove or treat the cancer being studied
- People whose cancer has spread to other parts of the body beyond the head and neck region
- People with other serious or uncontrolled health conditions, such as an active infection, or mental health or personal circumstances that may make it difficult to follow the study requirements
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: George Yang, MD, Moffitt Cancer Center
Phone: 813-745-5467
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Improvement in Mean OAR Dose Reduction
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.